Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03519412
Title Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA)
Acronym ARETHUSA
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors IFOM ETS - The AIRC Institute of Molecular Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Grande Ospedale Metropolitano Niguarda Milano Italy Details
Istituto Europeo di Oncologia Milano Italy Details
Istituto Nazionale Tumori di Milano Milano Italy Details
Istituto Clinico Humanitas Rozzano Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field